133 related articles for article (PubMed ID: 21218783)
1. Identification of diaryl ether-based ligands for estrogen-related receptor α as potential antidiabetic agents.
Patch RJ; Searle LL; Kim AJ; De D; Zhu X; Askari HB; O'Neill JC; Abad MC; Rentzeperis D; Liu J; Kemmerer M; Lin L; Kasturi J; Geisler JG; Lenhard JM; Player MR; Gaul MD
J Med Chem; 2011 Feb; 54(3):788-808. PubMed ID: 21218783
[TBL] [Abstract][Full Text] [Related]
2. Indazole-based ligands for estrogen-related receptor α as potential anti-diabetic agents.
Patch RJ; Huang H; Patel S; Cheung W; Xu G; Zhao BP; Beauchamp DA; Rentzeperis D; Geisler JG; Askari HB; Liu J; Kasturi J; Towers M; Gaul MD; Player MR
Eur J Med Chem; 2017 Sep; 138():830-853. PubMed ID: 28735214
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
Casimiro-Garcia A; Filzen GF; Flynn D; Bigge CF; Chen J; Davis JA; Dudley DA; Edmunds JJ; Esmaeil N; Geyer A; Heemstra RJ; Jalaie M; Ohren JF; Ostroski R; Ellis T; Schaum RP; Stoner C
J Med Chem; 2011 Jun; 54(12):4219-33. PubMed ID: 21557540
[TBL] [Abstract][Full Text] [Related]
4. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.
Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Halleux C; Kallen J; Keller H; Schlaeppi JM; Stark W
J Med Chem; 2003 Jul; 46(14):2945-57. PubMed ID: 12825935
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity.
Shi GQ; Dropinski JF; McKeever BM; Xu S; Becker JW; Berger JP; MacNaul KL; Elbrecht A; Zhou G; Doebber TW; Wang P; Chao YS; Forrest M; Heck JV; Moller DE; Jones AB
J Med Chem; 2005 Jun; 48(13):4457-68. PubMed ID: 15974597
[TBL] [Abstract][Full Text] [Related]
7. New beta-alanine derivatives are orally available glucagon receptor antagonists.
Lau J; Behrens C; Sidelmann UG; Knudsen LB; Lundt B; Sams C; Ynddal L; Brand CL; Pridal L; Ling A; Kiel D; Plewe M; Shi S; Madsen P
J Med Chem; 2007 Jan; 50(1):113-28. PubMed ID: 17201415
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological evaluation and molecular modeling studies of arylidene-thiazolidinediones with potential hypoglycemic and hypolipidemic activities.
da Costa Leite LF; Veras Mourão RH; de Lima Mdo C; Galdino SL; Hernandes MZ; de Assis Rocha Neves F; Vidal S; Barbe J; da Rocha Pitta I
Eur J Med Chem; 2007 Oct; 42(10):1263-71. PubMed ID: 17448573
[TBL] [Abstract][Full Text] [Related]
9. Substituted azaquinazolinones as modulators of GHSr-1a for the treatment of type II diabetes and obesity.
Hanrahan P; Bell J; Bottomley G; Bradley S; Clarke P; Curtis E; Davis S; Dawson G; Horswill J; Keily J; Moore G; Rasamison C; Bloxham J
Bioorg Med Chem Lett; 2012 Mar; 22(6):2271-8. PubMed ID: 22342626
[TBL] [Abstract][Full Text] [Related]
10. Flavone-based novel antidiabetic and antidyslipidemic agents.
Verma AK; Singh H; Satyanarayana M; Srivastava SP; Tiwari P; Singh AB; Dwivedi AK; Singh SK; Srivastava M; Nath C; Raghubir R; Srivastava AK; Pratap R
J Med Chem; 2012 May; 55(10):4551-67. PubMed ID: 22524508
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
[TBL] [Abstract][Full Text] [Related]
12. 2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
Johansson L; Fotsch C; Bartberger MD; Castro VM; Chen M; Emery M; Gustafsson S; Hale C; Hickman D; Homan E; Jordan SR; Komorowski R; Li A; McRae K; Moniz G; Matsumoto G; Orihuela C; Palm G; Veniant M; Wang M; Williams M; Zhang J
J Med Chem; 2008 May; 51(10):2933-43. PubMed ID: 18419108
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of oxime ethers of alpha-acyl-beta-phenylpropanoic acids as PPAR dual agonists.
Oon Han H; Kim SH; Kim KH; Hur GC; Joo Yim H; Chung HK; Ho Woo S; Dong Koo K; Lee CS; Sung Koh J; Kim GT
Bioorg Med Chem Lett; 2007 Feb; 17(4):937-41. PubMed ID: 17157019
[TBL] [Abstract][Full Text] [Related]
14. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
Upton R; Widdowson PS; Ishii S; Tanaka H; Williams G
Br J Pharmacol; 1998 Dec; 125(8):1708-14. PubMed ID: 9886762
[TBL] [Abstract][Full Text] [Related]
15. Discovery and structure-activity relationship of oxalylarylaminobenzoic acids as inhibitors of protein tyrosine phosphatase 1B.
Liu G; Szczepankiewicz BG; Pei Z; Janowick DA; Xin Z; Hajduk PJ; Abad-Zapatero C; Liang H; Hutchins CW; Fesik SW; Ballaron SJ; Stashko MA; Lubben T; Mika AK; Zinker BA; Trevillyan JM; Jirousek MR
J Med Chem; 2003 May; 46(11):2093-103. PubMed ID: 12747781
[TBL] [Abstract][Full Text] [Related]
16. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
17. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
Cobb JE; Blanchard SG; Boswell EG; Brown KK; Charifson PS; Cooper JP; Collins JL; Dezube M; Henke BR; Hull-Ryde EA; Lake DH; Lenhard JM; Oliver W; Oplinger J; Pentti M; Parks DJ; Plunket KD; Tong WQ
J Med Chem; 1998 Dec; 41(25):5055-69. PubMed ID: 9836622
[TBL] [Abstract][Full Text] [Related]
18. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Geiser M; Halleux C; Kallen J; Keller H; Ramage P
J Med Chem; 2005 Jan; 48(2):364-79. PubMed ID: 15658851
[TBL] [Abstract][Full Text] [Related]
19. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity.
Allen T; Zhang F; Moodie SA; Clemens LE; Smith A; Gregoire F; Bell A; Muscat GE; Gustafson TA
Diabetes; 2006 Sep; 55(9):2523-33. PubMed ID: 16936200
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor alpha coactivator binding.
Rodriguez AL; Tamrazi A; Collins ML; Katzenellenbogen JA
J Med Chem; 2004 Jan; 47(3):600-11. PubMed ID: 14736241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
